Background/Aims: In treating myasthenia gravis (MG), our aims were to achieve early minimal manifestations (MM) by performing early aggressive therapy (EAT) using plasmapheresis and high-dose intravenous methylprednisolone, and then to maintain the status with low-dose oral corticosteroids (EAT strategy). We examined the merits of the EAT strategy. Methods: We retrospectively analyzed long-term effects of the EAT strategy (duration of therapy: 4.1 years) for 49 de novo MG patients and compared the effects to those of high-dose oral prednisolone therapy for 22 patients. Results: The EAT group achieved marked early improve- ment with much lower doses of oral prednisolone compared to the high-dose prednisolone group. The patients who achieved MM with prednisolone ≤5 mg/day were more frequent in the EAT group at both 1 year (57.1 vs. 4.5%) and final observation (77.6 vs. 27.3%). Both new-onset diabetes and patients who had complained of moon face were less frequent in the EAT group. However, in the EAT group, due to a temporary inability to maintain MM, additional short-term hospitalizations to return to MM by EAT were required. Conclusions: The EAT strategy has advantages of early improvement with less frequent steroid-related complications. The labor and cost required are evident disadvantages.

1.
Patrick J, Lindstrom J: Autoimmune response to acetylcholine receptor. Science 1973;180:871–872.
2.
Meriggioli MN, Sanders DB: Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009;8:475–490.
3.
Gilhus NE: Autoimmune myasthenia gravis. Expert Rev Neurother 2009;9:351–358.
4.
Keesey JC: Clinical evaluation and management of myasthenia gravis. Muscle Nerve 2004;29:484–505.
5.
Pascuzzi RM, Coslett HB, Johns TR: Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984;15:291–298.
6.
Muscle Study Group: A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008;71:394–399.
7.
Sanders DB, Evoli A: Immunosuppressive therapies in myasthenia gravis. Autoimmunity 2010;43:428–435.
8.
Grob D, Brunner N, Namba T, Pagala M: Lifetime course of myasthenia gravis. Muscle Nerve 2008;37:141–149.
9.
Truhan AP, Ahmed AR: Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. Ann Allergy 1989;62:375–391.
10.
Brown ES, Suppes T: Mood symptoms during corticosteroid therapy: a review. Harvard Rev Psychiatry 1998;5:239–246.
11.
Aarli JA: Myasthenia gravis in the elderly: is it different? Ann NY Acad Sci 2008;1132:238–243.
12.
Evoli A, Batocchi AP, Minisci C, Di Schino C, Tonali P: Clinical characteristics and prognosis of myasthenia gravis in older people. J Am Geriatr 2000;48:1442–1448.
13.
Vincent A, Clover L, Buckley C, Grimley EJ, Rothwell PM: Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 2003;74:1105–1108.
14.
Somnier FE: Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis. Neurology 2005;65:928–930.
15.
Munakata R, Utsugisawa K, Nagane Y, Yamagata M, Oikawa M, Obara D, Tohgi H: The effect of combined therapy with immunoadsorption and high-dose intravenous methylprednisolone on myasthenia gravis. Eur Neurol 2002;48:115–117.
16.
Nagane Y, Utsugisawa K, Obara D, Kondoh R, Terayama Y: Efficacy of low-dose FK506 in the treatment of myasthenia gravis – a randomized pilot study. Eur Neurol 2005;53:146–150.
17.
Newsom-Davis J, Wilson SG, Vincent A, Ward CD: Long-term effects of repeated plasma exchange in myasthenia gravis. Lancet 1979;1:464–468.
18.
Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al: Myasthenia gravis: recommendation for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16–23.
19.
Sato T, Anno M, Arai K, Yamawaki N, Kuroda T, Inagaki K: In vitro removal of anti-acetylcholine receptor antibodies with a new immunoadsorbent in sera from myasthenia gravis patients; in Atsumi K, Maekawa M, Ota K (eds): Progress in Artificial Organs. Cleveland, ISAO Press, 1983, pp 719–722.
20.
Shibuya N, Sato T, Osame M, Takegami T, Doi S, Kawanami S: Immunoadsorption therapy for myasthenia gravis. J Neurol Neurosurg Psychiatry 1994;57:578–581.
21.
Tindall RSA, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G: Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987;316:719– 724.
22.
Nagane Y, Suzuki S, Suzuki N, Utsugisawa K: Factors associated with response to calcineurin inhibitors in myasthenia gravis. Muscle Nerve 2010;41:212–218.
23.
Slesak G, Melms A, Gerneth F, Sommer N, Weissert R, Dichgans J: Late-onset myasthenia gravis. Follow-up of 113 patients diagnosed after age 60. Ann NY Acad Sci 1998;841:777–780.
24.
Zinman L, Ng E, Bril V: IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007;68:837–841.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.